JHS Svendgaard Laboratories Ltd (JHS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by JHS Svendgaard Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Un-Audited Financial Results for the Quarter and Half year Ended 30th September, 2026.
Financial Result · 04 Nov 2026, 5:35 pm
JHS Svendgaard Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 2,183 (-2.0% YoY | -28.1% QoQ) ■ EBITDA: 51.2 (-43.7% YoY | -75.3% QoQ) ■ EBITDA Margin (%): 2.3 (-173 bps YoY | -448 bps QoQ) ■ PAT: 50.6 (Loss to Profit YoY | -53.6% QoQ) ■ EPS (INR): 0.06 (Loss to Profit YoY | -50.0% QoQ)
Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2026
Revision of outcome · 04 Nov 2026, 5:29 pm
JHS Svendgaard Laboratories Reports Q2 FY27 Results and Board Appointment JHS Svendgaard Laboratories reported consolidated revenue from operations of Rs 2,182.89 lakhs for the quarter ended 30th Sep'26, down 2.0% YoY from Rs 2,227.71 lakhs and down 28.1% QoQ from Rs 3,038.05 lakhs. Net profit for the period turned positive at Rs 50.62 lakhs compared to a net loss of Rs 19.77 lakhs in 30th Sep'25, aided by deferred and prior-period tax credits. The Board also approved appointing retired IPS officer Pardeep Kumar Bhardwaj as Additional Non-Executive Independent Director for five years.
Statement of Deviation and Variation for the quarter ended 30 September, 2026.
Others (Uncategorized) · 03 Nov 2026, 12:27 am
JHS Svendgaard Laboratories Reports Fund Allocation Variations for Preferential Issue Proceeds JHS Svendgaard Laboratories Limited disclosed shareholder-approved modifications, dated 29th Jul'26, regarding the utilization of ₹29.99 crore raised via a preferential issue on 4th Jun'24. For the quarter ended 30th Sep'26, capital expenditure and business expansion allocation was increased from ₹5.9999 crore to ₹11.7499 crore (₹8.4946 crore utilized), while group entity infusion was revised down to ₹10.75 crore for strategic and growth initiatives (₹9.625 crore utilized). General corporate purpose allocation remained unchanged at ₹7.50 crore and is fully utilized. Zero deviation was reported against the modified objects.
Board of Directors approved the appointment of Mr. Pardeep Kumar Bhardwaj as an Additional Non-Executive Independent Director of the Company.
Change in Management · 03 Nov 2026, 12:12 am
JHS Svendgaard Appoints Pardeep Kumar Bhardwaj as Independent Director JHS Svendgaard Laboratories Limited approved the appointment of Mr. Pardeep Kumar Bhardwaj as an Additional Non-Executive Independent Director for a 5-year term effective 2nd Nov'26, subject to shareholder approval. A retired IPS officer and former Special Commissioner of Delhi Police, Mr. Bhardwaj also served as Electricity Ombudsman at DERC. Concurrently, the company reconstituted its Audit Committee and Nomination and Remuneration Committee to include Mr. Bhardwaj as a member, enhancing board oversight and corporate governance.
Board of Directors in their meeting dated 02 November, 2026 approved the unaudited Standalone and Consolidated financials for quarter and half year ended 30 September, 2026.
Financial Result · 03 Nov 2026, 12:05 am
JHS Svendgaard Laboratories Limited has submitted to the Exchange, Un-audited-financial results for the period ended September 30, 2026.
Outcome · 02 Nov 2026, 11:57 pm
Board of Directors approved the unaudited standalone and consolidated financials for quarter and half year ended 30 September, 2026.
Outcome · 02 Nov 2026, 11:56 pm
JHS Svendgaard Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 2,183 (-2.0% YoY | -28.1% QoQ) ■ EBITDA: 51.2 (-43.7% YoY | -75.3% QoQ) ■ EBITDA Margin (%): 2.3 (-173 bps YoY | -448 bps QoQ) ■ PAT: 50.6 (Loss to Profit YoY | -53.6% QoQ) ■ EPS (INR): 0.06 (Loss to Profit YoY | -50.0% QoQ)
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
JHS SVENDGAARD LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve the Un-Audited ....
Intimation · 02 Nov 2026, 5:30 am
JHS Svendgaard Laboratories Schedules Board Meeting for Q2 FY27 Financial Results JHS Svendgaard Laboratories Limited has scheduled its Board of Directors meeting for 2nd Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the company's trading window closed on 1st Oct'26 and will remain shut until 48 hours following the official announcement of the financial results.
Scrutinizer Report for the 22nd AGM held on 26th September, 2026
Annual General Meeting · 29 Sept 2026, 9:49 pm
Proceedings of 22nd Annual General Meeting for the Financial Year ended 2025-26.
Annual General Meeting · 26 Sept 2026, 10:28 pm
Please find enclosed copy of letter containing web-link for annual report 2025-26 being sent to shareholder of Company whose E-mail id not registered.
Annual Report · 17 Sept 2026, 4:41 pm
Notice of 22nd Annual General Meeting of the Company is scheduled to be held on September 26, 2026, at 3:00 PM
Annual General Meeting · 02 Sept 2026, 9:50 pm
Annual Report for the Financial Year 2025-26
Others (Uncategorized) · 02 Sept 2026, 9:44 pm
Statement of Deviation and Variation for the Quarter Ended 30th June, 2026
Others (Uncategorized) · 11 Aug 2026, 10:30 pm
JHS Svendgaard Reports No Deviation in Fund Utilization for Q1FY27 JHS Svendgaard Laboratories reported no deviation in the utilization of funds for the quarter ended 30 Jun'26. The company raised Rs. 29.99 crores via a preferential issue on 04 Jun'24. Originally, Rs. 22.50 crores were allocated for a new project in Jammu & Kashmir and Rs. 7.50 crores for general corporate purposes. The objects were modified to include Rs. 7.65 crores for capital expenditure and Rs. 11.10 crores for strategic fund infusion into group entity JHS Svendgaard Retail Ventures Ltd.
The Board of Directors approved the Un-Audited Financial Results for the Quarter Ended 30th June, 2026
Outcome · 11 Aug 2026, 10:24 pm
JHS Svendgaard Q1FY27: Revenue Rises 29% YoY, Profit Remains Flat JHS Svendgaard Laboratories reported a standalone net profit of ₹109.15 lakhs for Q1FY27, a slight increase from ₹105.57 lakhs in Q1FY26. Revenue from operations grew 29.5% YoY to ₹3,038.05 lakhs. However, performance declined sequentially, with revenue down 7.1% QoQ and net profit falling sharply from a loss of ₹356.56 lakhs in Q4FY26. Total expenses increased by 27.6% YoY to ₹3,040.82 lakhs, primarily driven by higher material costs. Basic EPS for the quarter was ₹0.13, compared to ₹0.12 YoY.
The Board of Directors in its meeting held on 11th August, 2026 inter alia Considered and Approved the Un-Audited Financial Results for the Quarter Ended 30th June, 2026
Financial Result · 11 Aug 2026, 10:20 pm
JHS Svendgaard Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 3,038 (+29.5% YoY | -7.1% QoQ) ■ EBITDA: 207 (+24.7% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 6.8 (-26 bps YoY | Loss to Profit QoQ) ■ PAT: 109 (+3.3% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.12 (+0.0% YoY | Loss to Profit QoQ)
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Un-Audited Financial ....
Intimation · 11 Aug 2026, 5:30 am
JHS Svendgaard Laboratories Board Meeting Set for Aug 11 to Approve Q1FY27 Results JHS Svendgaard Laboratories will hold a Board of Directors meeting on 11 Aug'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter ended 30 Jun'26. In accordance with SEBI regulations, the trading window for insiders has been closed since 01 Jul'26 and will reopen 48 hours after the financial results are announced. This meeting is a key event for the upcoming Q1FY27 earnings release.
Outcome of Board meeting regarding variation in the utilization of proceeds raised through preferential issue as approved by shareholders through postal ballot on June 23, 2025.
Outcome · 25 Jun 2026, 10:37 pm
JHS Svendgaard Reallocates Preferential Issue Proceeds for Expansion and Growth JHS Svendgaard's Board, on 25 Jun'26, approved a variation in utilising ₹2,999.99 lakh from a preferential issue. The amendment reallocates funds towards Capital Expenditure & Business Expansion (₹1,174.99 lakh) and Strategic, Financial & Growth Initiatives (₹1,075.00 lakh), while General Corporate Purpose remains at ₹750.00 lakh. This modification provides greater flexibility for acquisitions and strategic investments. The timeline for utilising these funds has been extended from Dec'26 to 31 Mar'27, pending shareholder approval.
Statement of Deviation for Quarter ended 31 March, 2026.
Others (Uncategorized) · 27 May 2026, 1:08 am
JHS Svendgaard Reports No Deviation in Use of Preferential Issue Funds JHS Svendgaard Laboratories reports no deviation in the utilization of Rs. 29.99 crores raised via a preferential issue on 04 Jun'24. For the quarter ended 31 Mar'26, the company confirmed fund allocation changes: capital expenditure allocation was reduced from Rs. 22.50 crores to Rs. 6.00 crores, and Rs. 16.50 crores were reallocated for strategic fund infusion into its group entity, JHS Svendgaard Retail Ventures Ltd., for expansion. The audit committee and auditors had NIL comments, confirming compliance.
Audited Financial Result for quarter and year ended 31 March, 2026.
Financial Result · 27 May 2026, 12:37 am
JHS Svendgaard Q4FY26 Results: Widened Loss Amid Higher Revenue and Expenses JHS Svendgaard reported a consolidated net loss of ₹356.86 lakhs for Q4FY26, widening from a loss of ₹192.24 lakhs for FY26. Revenue from operations increased 29.9% YoY to ₹3,269.57 lakhs, while total expenses grew by 11.0% YoY to ₹3,640.45 lakhs. For FY26, revenue stood at ₹10,169.47 lakhs versus ₹9,199.73 lakhs in FY25. The Board approved the audited results on 26 May '26, which included an unmodified opinion from the auditors. Basic EPS for Q4FY26 was (₹0.42).
The Board of Directors of the company inter alia, considered and approved the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2025 today in its ....
Outcome · 27 May 2026, 12:26 am
JHS Svendgaard Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 3,270 (+29.9% YoY | +40.5% QoQ) ■ EBITDA: -163 (+69.7% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -5.0 (+1638 bps YoY | Profit to Loss QoQ) ■ PAT: -357 (+48.7% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.42 (+50.0% YoY | Profit to Loss QoQ)
JHS Svendgaard Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Audited Financial ....
Intimation · 26 May 2026, 5:30 am
JHS Svendgaard Board to Approve Q4FY26 Financial Results on May 26 JHS Svendgaard Laboratories announced a Board of Directors meeting scheduled for 26 May '26. The agenda includes consideration and approval of the audited standalone and consolidated financial results for the quarter and financial year ended 31 Mar '26. The trading window for insiders has been closed from 01 Apr '26 and will reopen 48 hours after the results are announced.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 4:31 pm
JHS Svendgaard Laboratories Confirms It Is Not a "Large Corporate" JHS Svendgaard Laboratories Limited announced on 30 Apr'26 that it does not qualify as a "Large Corporate" under the SEBI framework for fundraising via debt securities. The company disclosed that its outstanding borrowings stood at ₹13.87 crore as of 31 Mar'26. This classification exempts the company from the mandatory requirement to raise a portion of its incremental borrowings through debt instruments, a rule applicable only to entities designated as Large Corporates by the regulator.